VRTXVertex Pharmaceuticals Incorporated

$129B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.0B+12.1% YoY

Gross Profit

$2.6B86.3% margin

Operating Income

$1.2B38.8% margin

Net Income

$1.0B34.8% margin

EPS (Diluted)

$3.99

QoQ Revenue Growth

+7.0%

Cash Flow

Operating Cash Flow

$1.1B

Free Cash Flow

$927M

Stock-Based Comp.

$167M

Balance Sheet

Total Assets

$24.0B

Total Liabilities

$6.9B

Stockholders' Equity

$17.2B

Cash & Equivalents

$5.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.0B	$2.6B	+12.1%
Gross Profit	$2.6B	$2.3B	+12.5%
Operating Income	$1.2B	-$3.5B	+132.8%
Net Income	$1.0B	-$3.6B	+128.7%

Revenue Segments

TRIKAFTA/KAFTRIO

$2.6B87%

Manufactured Product, Other

$236M8%

ALYFTREK

$157M5%

Geographic Segments

UNITED STATES

$1.8B62%

Europe

$911M31%

Other, Non U.S.

$206M7%

VRTX Q2 2025 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena